A study of the diagnostic value of Inhibin A Tests for occurrence of preeclampsia in pregnant women

• Main Authors: Farzaneh Broumand, Shaker Salari Lak, Farhad Nemati, Atefeh Mazidi
• Format: Article
• Language: English
• Published: Electronic Physician 2018-01-01
• Series: Electronic Physician
• Subjects: Pre-Eclampsia; Inhibin A; Pregnancy tests
• Online Access: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5853992/
• ISSN: 2008-5842; 2008-5842

Background: Hypertensive disorders are common during pregnancy, and are among 3 important causes of maternal death. Preeclampsia occurs in 3 to 5% of pregnancies. Early diagnosis of this disorder can lead to better pregnancy outcomes. Objective: The aim of this study was to determine the relationship between inhibin A serum levels during second stage pregnancy screening tests, and incidence and severity of preeclampsia. Methods: In this study, 300 pregnant women who referred to Kowsar Hospital and carried out second stage pregnancy screening tests from September 2014 to March 2015 in Urmia city, Iran, were enrolled. Five ml venous blood samples were obtained from each participant, and inhibin A serum levels were evaluated in all cases. Finally, all the necessary information was obtained from the pregnancy files of participants after delivery, and gathered in a questionnaire. The data were analyzed using SPSS software version 18 and independent t-test, ANOVA and descriptive statistics were used. P-values less than 0.05 were considered significant. Results: Among the 300 pregnant women who were studied, the gestational age at the time of acquiring blood samples was as follows: 169 cases (56.3%) at 16-17 weeks, 77 cases (25.7%) at 18-19 weeks and 14 cases at 20 weeks (4.7%). In this study, MOM of inhibin A was more than 1.25 in 12 cases that finally, preeclampsia occurred in them. This relationship was statistically significant (p=0.001). The relationship between MOM of inhibin A and severe preeclampsia was evaluated, and the relationship was significant (p=0.004). The relationship between MOM of inhibin A and pregnancy hypertension was not significant (p=0.643). Conclusion: Considering the results of this study, we can conclude that MOM of inhibin A levels in maternal serum during second stage pregnancy screening tests can predict incidence and severity of developing preeclampsia in pregnant women. This is not true in cases of pregnancy hypertension.